A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma.
Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.
Eickhoff
A
A
Medical Department C, Klinikum Ludwigshafen gGmbH, Bremserstr.79, Ludwigshafen D-67063, Germany. eickhofa@klilu.de
Martin
W
W
Hartmann
D
D
Eickhoff
J C
JC
Möhler
M
M
Galle
P R
PR
Riemann
J F
JF
Jakobs
R
R
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000627:therapeutic use* / Q000633:toxicity*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D010976:Platelet Count; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D006454:Hemoglobins; D003841:Deoxycytidine; D015251:Epirubicin; D000093542:Gemcitabine